Separation of outer retinal layers secondary to selumetinib

被引：19

作者：

Avery, Robert A. ^{[1
,2
]}

Trimboli-Heidler, Carmelina ^{[1
]}

Kilburn, Lindsay B. ^{[3
,4
]}

机构：

[1] Childrens Natl Hlth Syst, Gilbert Family Neurofibromatosis Inst, Washington, DC USA

[2] Childrens Natl Hlth Syst, Ctr Neurosci & Behav, Washington, DC USA

[3] Childrens Natl Hlth Syst, Ctr Canc & Blood Disorders, Div Oncol, Washington, DC USA

[4] Childrens Natl Hlth Syst, Brain Tumor Inst, Washington, DC USA

来源：

JOURNAL OF AAPOS | 2016年 / 20卷 / 03期

关键词：

INHIBITORS;

D O I：

10.1016/j.jaapos.2016.01.012

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

New therapeutic agents targeting the mitogen-activated protein (MAP) kinase pathway, including MEK inhibitors, are currently being evaluated in phase 1 and 2 clinical trials for pediatric brain tumors. Ophthalmologic side effects from MEK inhibitors have previously only been reported in adults and included retinal vein occlusion, central retinal artery occlusion, and separation of the neurosensory retina. We report 2 patients with optic pathway gliomas who developed outer retinal layer separation visualized by optical coherence tomography while taking the MEK inhibitor selumetinib. After discontinuation of selumetinib, the outer retinal layer separation resolved without visual sequelae. One patient has been retreated with selumetinib and experienced recurrence of these findings.

引用

页码：268 / 271

页数：4

共 7 条

[1] The molecular and cell biology of pediatric low-grade gliomas [J].

Chen, Y-H ;

Gutmann, D. H. .

ONCOGENE, 2014, 33 (16) :2019-2026

[2] MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity [J].

Duncan, K. E. ;

Chang, L. Y. ;

Patronas, M. .

EYE, 2015, 29 (08) :1003-1012

[3] From basic research to clinical development of MEK1/2 inhibitors for cancer therapy [J].

Fremin, Christophe ;

Meloche, Sylvain .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3

[4] PD0325901, a Mitogen-Activated Protein Kinase Kinase Inhibitor, Produces Ocular Toxicity in a Rabbit Animal Model of Retinal Vein Occlusion [J].

Huang, Wenhu ;

Yang, Amy H. ;

Matsumoto, Diane ;

Collette, Walter ;

Marroquin, Lisa ;

Ko, Mira ;

Aguirre, Shirley ;

Younis, Husam S. .

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2009, 25 (06) :519-530

[5] Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers [J].

LoRusso, Patricia M. ;

Krishnamurthi, Smitha S. ;

Rinehart, John J. ;

Nabell, Lisle M. ;

Malburg, Lisa ;

Chapman, Paul B. ;

DePrimo, Samuel E. ;

Bentivegna, Steven ;

Wilner, Keith D. ;

Tan, Weiwei ;

Ricart, Alejandro D. .

CLINICAL CANCER RESEARCH, 2010, 16 (06) :1924-1937

[6] Bilateral Subfoveal Neurosensory Retinal Detachment Associated With MEK Inhibitor Use for Metastatic Cancer [J].

McCannel, Tara A. ;

Chmielowski, Bartosz ;

Finn, Richard S. ;

Goldman, Jonathan ;

Ribas, Antoni ;

Wainberg, Zev A. ;

McCannel, Colin A. .

JAMA OPHTHALMOLOGY, 2014, 132 (08) :1005-1009

[7] Toxicology of the retina: advances in understanding the defence mechanisms and pathogenesis of drug- and light-induced retinopathy [J].

Siu, Timothy L. ;

Morley, John W. ;

Coroneo, Minas T. .

CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2008, 36 (02) :176-185

← 1 →